Published in J Infect Dis on October 01, 2008
Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol (2009) 2.17
Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India (2012) 1.40
A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis (2010) 1.10
Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother (2016) 1.03
Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother (2013) 1.03
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 0.99
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother (2015) 0.91
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother (2013) 0.89
The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun (2011) 0.88
Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial. J Infect Dis (2014) 0.87
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis (2012) 0.86
A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One (2014) 0.84
Adult survivors of invasive pneumococcal disease exhibit defective B cell function. Clin Infect Dis (2011) 0.81
Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right? Clin Vaccine Immunol (2016) 0.78
Is there a potential role for protein-conjugate pneumococcal vaccine in older adults? Australas Med J (2012) 0.78
Recommended Vaccinations for Asplenic and Hyposplenic Adult Patients. Hum Vaccin Immunother (2016) 0.77
Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy. J Int AIDS Soc (2016) 0.76
Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial. Hum Vaccin Immunother (2015) 0.75
Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults. Hum Vaccin Immunother (2016) 0.75
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1997) 7.36
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med (1991) 6.07
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med (2003) 5.60
Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J (2007) 3.99
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis (1999) 3.15
Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis (2004) 3.11
Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med (1980) 2.85
Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med (2007) 2.11
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2003) 1.88
Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis (2007) 1.87
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 1.76
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis (2007) 1.64
Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J (2006) 1.57
Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol (2003) 1.54
Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis (2006) 1.52
Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) (2000) 1.50
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
Pneumococcal polysaccharide vaccines do not protect the elderly from pneumococcal infections. Neth J Med (2004) 1.41
Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J Immunol (1950) 1.40
Pneumococcus: the first one hundred years. Rev Infect Dis (1981) 1.36
The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine (2004) 1.34
Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med (2006) 1.32
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Investig Med (1997) 1.29
The human antibody response to simultaneous injection of six specific polysaccharides of pneumococcus. J Exp Med (1948) 1.22
Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun (1997) 1.19
Activation of antigen-specific suppressor T cells by B cells from mice immunized with type III pneumococcal polysaccharide. J Exp Med (1983) 1.19
Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis (1996) 1.15
Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine (2000) 1.13
Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis (1996) 1.10
Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine (2003) 1.08
Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis (1996) 1.03
Immunological paralysis to pneumococcal polysaccharide in man. Lancet (1985) 0.88
Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniae. Clin Vaccine Immunol (2007) 0.82
Vaccination-induced activation of human blood T cells suppressing pneumococcal polysaccharide-specific B cells. Acta Pathol Microbiol Immunol Scand C (1987) 0.81
Production of soluble suppressor factor by spleen cells from mice immunized with type III pneumococcal polysaccharide. J Immunol (1985) 0.80
Different types of immunological unresponsiveness. Adv Exp Med Biol (1973) 0.77
Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol (2007) 7.44
Genetic basis for the new pneumococcal serotype, 6C. Infect Immun (2007) 5.27
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
spa typing method for discriminating among Staphylococcus aureus isolates: implications for use of a single marker to detect genetic micro- and macrovariation. J Clin Microbiol (2004) 4.80
Veterans Aging Cohort Study (VACS): Overview and description. Med Care (2006) 4.34
Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog (2006) 3.68
Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J Infect Dis (2005) 3.32
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med (2010) 3.00
Increased COPD among HIV-positive compared to HIV-negative veterans. Chest (2006) 2.93
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) (2002) 2.75
Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 2.71
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med (2005) 2.58
Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology (2009) 2.56
Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis (2003) 2.50
Validation of a multiplex pneumococcal serotyping assay with clinical samples. J Clin Microbiol (2006) 2.48
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol (2008) 2.42
Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2006) 2.34
Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr (2003) 2.33
Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med (2014) 2.29
A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J Infect Dis (2010) 2.23
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol (2006) 2.20
Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health (2003) 2.16
Long-term survival following pneumococcal pneumonia. Clin Infect Dis (2013) 2.15
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med (2012) 2.14
Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One (2011) 2.11
HIV infection and the risk of diabetes mellitus. AIDS (2009) 2.10
Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr (2009) 2.09
Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med (2011) 2.08
Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology (2009) 2.07
Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol (2006) 2.05
Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis (2014) 2.03
A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc Natl Acad Sci U S A (2008) 2.02
Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol (2007) 2.01
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol (2006) 2.00
Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of a new pneumococcal serotype. J Biol Chem (2012) 1.90
Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One (2007) 1.89
Portable, battery-operated, low-cost, bright field and fluorescence microscope. PLoS One (2010) 1.88
Rapid multiplex assay for serotyping pneumococci with monoclonal and polyclonal antibodies. J Clin Microbiol (2005) 1.79
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J Infect Dis (2004) 1.75
Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev (2009) 1.72
Medical ICU admission diagnoses and outcomes in human immunodeficiency virus-infected and virus-uninfected veterans in the combination antiretroviral era. Crit Care Med (2013) 1.71
Validating smoking data from the Veteran's Affairs Health Factors dataset, an electronic data source. Nicotine Tob Res (2011) 1.69
rpoB Gene mutations and molecular characterization of rifampin-resistant Mycobacterium tuberculosis isolates from Shandong Province, China. J Clin Microbiol (2006) 1.68
Association between interleukin-8 gene alleles and human susceptibility to tuberculosis disease. J Infect Dis (2003) 1.68
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine (2011) 1.61
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2006) 1.57
Rarely occurring 19A-like cps locus from a serotype 19F pneumococcal isolate indicates continued need of serology-based quality control for PCR-based serotype determinations. J Clin Microbiol (2009) 1.55
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med (2008) 1.55
Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol (2003) 1.54
A chemokine-degrading extracellular protease made by group A Streptococcus alters pathogenesis by enhancing evasion of the innate immune response. Infect Immun (2008) 1.54
Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis (2009) 1.54
Group A Streptococcus gene expression in humans and cynomolgus macaques with acute pharyngitis. Infect Immun (2003) 1.53
Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis (2006) 1.52
The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis (2007) 1.52
Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect Immun (2003) 1.51
Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infect Dis (2013) 1.50
Detection of Clostridium difficile toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. J Clin Microbiol (2007) 1.49
Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun (2010) 1.49
Epidemiology of tuberculosis in young children in the United States. Pediatrics (2014) 1.49
Evaluation of QuantiFERON-TB gold in-tube and tuberculin skin tests among immigrant children being screened for latent tuberculosis infection. Pediatr Infect Dis J (2015) 1.45
Molecular characteristics of nosocomial and Native American community-associated methicillin-resistant Staphylococcus aureus clones from rural Wisconsin. J Clin Microbiol (2004) 1.45
Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg (2009) 1.41
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol (2009) 1.38
Association of age and comorbidity with physical function in HIV-infected and uninfected patients: results from the Veterans Aging Cohort Study. AIDS Patient Care STDS (2011) 1.37
Pulsed-field gel electrophoresis study of Mycobacterium abscessus isolates previously affected by DNA degradation. J Clin Microbiol (2004) 1.37
Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. J Med Microbiol (2004) 1.37
Differences between infectious diseases-certified physicians and general medicine-certified physicians in the level of comfort with providing primary care to patients. Clin Infect Dis (2005) 1.33
Tuberculosis disparity between US-born blacks and whites, Houston, Texas, USA. Emerg Infect Dis (2009) 1.33
Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med (2011) 1.31
Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg (2005) 1.30
From Quellung to multiplex PCR, and back when needed, in pneumococcal serotyping. J Clin Microbiol (2012) 1.30
Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease. Proc Natl Acad Sci U S A (2005) 1.30
Examining the link between patient satisfaction and adherence to HIV care: a structural equation model. PLoS One (2013) 1.27
Genetic diversity among type emm28 group A Streptococcus strains causing invasive infections and pharyngitis. J Clin Microbiol (2005) 1.26
Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis (2013) 1.26
Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem (2013) 1.24
Risk factors for hospitalization and medical intensive care unit (MICU) admission among HIV-infected Veterans. J Acquir Immune Defic Syndr (2013) 1.23
Common nonsynonymous polymorphisms in the NOD2 gene are associated with resistance or susceptibility to tuberculosis disease in African Americans. J Infect Dis (2008) 1.23
Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio (2012) 1.22
Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis. Antimicrob Agents Chemother (2005) 1.22
Identifying drivers of overall satisfaction in patients receiving HIV primary care: a cross-sectional study. PLoS One (2012) 1.21
Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med (2008) 1.21
Mycobacterium simae outbreak associated with a hospital water supply. Infect Control Hosp Epidemiol (2004) 1.21
Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans. J Gen Intern Med (2007) 1.19
Laparoscopic colon resection early in the learning curve: what is the appropriate setting? Ann Surg (2006) 1.19
Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) (2011) 1.19
Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab (2002) 1.18
Low-cost, high-throughput, automated counting of bacterial colonies. Cytometry A (2010) 1.18
Comparing the tuberculin skin test and T-SPOT.TB blood test in children. Pediatrics (2010) 1.17
Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol (2006) 1.16
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin (2011) 1.15